“Neutral” rating was Reiterated at B. Riley FBR. Mallinckrodt (NYSE:MNK) Has Given Price Target Of $20.

June 29, 2018 - By Carey Conley

During Q1 2018 the big money sentiment increased to 0.9. That’s change of 0.19, from 2017Q4’s 0.71. 38 investors sold all, 85 reduced holdings as Mallinckrodt Public Limited Company ratio improved. 64 rose holdings while 47 funds acquired holdings. Funds hold 96.44 million shares thus 6.30% more from 2017Q4’s 90.73 million shares.

Utah Retirement System reported 0.01% in Mallinckrodt Public Limited Company (NYSE:MNK). Point72 Asset Mgmt Lp invested 0.04% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). Panagora Asset Mngmt Inc has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Envestnet Asset Mngmt reported 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK). West Oak Ltd Liability Com holds 0% or 75 shs in its capital. Massachusetts-based State Street Corporation has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). D E Shaw & has invested 0.03% in Mallinckrodt Public Limited Company (NYSE:MNK). 216,289 were reported by Citigroup. Jacobs Levy Equity owns 83,700 shs. Bnp Paribas Arbitrage Sa invested in 0% or 190,170 shs. Comerica National Bank & Trust reported 68,492 shs. Ny State Teachers Retirement holds 190,501 shs or 0.01% of its capital. Rhumbline Advisers has 193,533 shs for 0.01% of their capital. Legal General Grp Pcl has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Royal Bancshares Of Canada reported 0% in Mallinckrodt Public Limited Company (NYSE:MNK).

Mallinckrodt Public Limited Company had 1 insider sale and 1 buying transaction since May 9, 2018. This’s net activity of $4.14 million. Trudeau Mark bought 3,000 shs worth $46,615.

Reiterated Mallinckrodt (NYSE:MNK) Rating.

Mallinckrodt (NYSE:MNK)‘s stock “Neutral” rating was reconfirmed by B. Riley FBR on 28 June. The broker’s Stock research analysts have a $20 price target and indicates a potential upside of 7.18 % on the stock.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Total analysts of 12 have positions in Mallinckrodt (NYSE:MNK) as follows: 4 rated it a “Buy”, 1 with “Sell” and 7 with “Hold”. The positive are 33%. Since January 3, 2018 according to StockzIntelligence Inc Mallinckrodt has 22 analyst reports. On Friday, April 20 the firm has “Hold” rating given by Mizuho. On Thursday, April 12 the company was downgraded by Stifel Nicolaus. On Tuesday, May 8 the rating was maintained by Cantor Fitzgerald with “Buy”. On Monday, April 2 the stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Cantor Fitzgerald. On Wednesday, May 9 the company was maintained by Morgan Stanley. On Tuesday, February 27 the firm has “Buy” rating by Jefferies given. The stock rating was maintained by Mizuho with “Hold” on Tuesday, February 27. On Monday, April 23 the firm earned “Hold” rating by Leerink Swann. The company rating was maintained by Mizuho on Tuesday, January 9. On Friday, May 18 the rating was maintained by Mizuho with “Hold”.

The stock decreased 2.71% or $0.52 during the last trading session, reaching $18.66.Mallinckrodt Public Limited Company has volume of 1.25 million shares. Since June 29, 2017 MNK has declined 59.76% and is downtrending. MNK underperformed the S&P 500 by 72.33%.

Investors expect Mallinckrodt Public Limited Company (NYSE:MNK)’s quarterly earnings on August, 14., according to Faxor. Analysts predict 19.46 % diference or $1.49 from the $1.85 EPS from 2017. If earnings per share of $1.49 is published the profit of MNK could be $123.77 million giving it 3.13 P/E. After $1.31 earnings per share was published last quarter, analysts now see EPS growth of 13.74 % for Mallinckrodt Public Limited Company.

Mallinckrodt public limited company develops, makes, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions.The firm is worth $1.55 billion. The firm markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.1.02 is the P/E ratio. It offers H.P.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were posted by Streetinsider.com, Seekingalpha.com and Streetinsider.com. The first one has “Aurobindo Said in Advanced Talks to buy Mallinckrodt’s (MNK) Specialty Generics Business – CNBC-TV18” as a title and was posted on June 28, 2018. The next is “Mallinckrodt: The Cheapest Stock In Global Healthcare” on June 08, 2018. And last was posted on June 28, 2018, called “Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for HP Acthar …”.

Mallinckrodt Public Limited Company (NYSE:MNK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.